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1436A 38-year-old man received a myeloablative conditioning regimen and peripheral blood stem cell transplant
(PBSCT) from his HLA identical sister for acute myelogenous leukemia (AML) in an early second relapse. The patient
developed grade II acute graft-versus-host disease (aGVHD) on day 40 after transplantation, which responded
promptly to steroids at 2 mg/kg/day. A steroid taper was begun. When his steroid dose reached 0.25 mg/kg/day,
a new raised rash with plaque-like lesions involving 36% of his body surface area and mouth sores developed. Liver
function tests were 5 times normal and a platelet count was 40,000. Steroids were increased to 1 mg/kg/day for
the diagnosis of chronic GVHD (cGVHD), and tacrolimus was continued. Unfortunately, when seen 2 weeks later
his skin rash was almost confluent, oral examination showed an extensive lichen planus-like eruption, liver function
tests were now 10 times normal, and his platelet count was 20,000. The patient is quite symptomatic, and reports
that he lost 20 pounds and is unable to accomplish his normal activities.
What therapy would you recommend?
 Continue current therapy—the patient has had an inadequate steroid trial to evaluate his response
 Add PUVA (Psoralen and UVA light)
 Add mycophenolate mofetil (MMF)
 Add rituximab
 Add sirolimus
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In a recent issue of the ASBMT eNEWS, readers
were presented with the above Clinical Challenge
and invited to use an online poll to recommend a course
of treatment. The reader recommendations for ther-
apy were:
 54% Add mycophenolate mofetil
 17% Add PUVA (Psoralen and UVA light)
 15% Add sirolimus
 10% Add rituximab
 5% Continue current therapy—the patient has had
an inadequate steroid trial to evaluate his response
COMMENTARY
This patient has very high-risk, steroid-refractory
chronic graft-versus-host disease (cGVHD), because
he has progressed despite appropriate doses of ste-
roids administered for at least 2 weeks [1]. Therefore,
continuing current therapy would not be a desirable
therapeutic option in this patient. Some manifesta-
tions in our patient are reminiscent of acute GVHD
(aGVHD) and such late presentations of aGVHD
manifestations are associated with worse survival in
cGVHD studies [2]. Unfortunately, the prognosis-8791/08/1412-0001$34.00/0
0.1016/j.bbmt.2008.05.016for this patient is grim, and the best therapy is not
known [3]. If a clinical trial is available, we would
strongly recommend enrolling this patient to help
us determine the best treatment for patients with
multiple high-risk features not responding to primary
steroid-based therapy. The options listed are not op-
timal. In this poll 17% of respondents recommended
PUVA. PUVA therapy has been shown to be helpful
in patients with skin (lichen planus-like) disease only,
but not systemic disease as seen in this patient [4].
Phototherapy (not given as an option in this poll) is
more commonly delivered in the form of extracorpo-
real photopheresis (ECP) and could be considered as
it may control systemic GVHD, whereas theoretically
maintaining the desired graft-versus-leukemia (GVL)
effect. But the rapid progression of the patient’s
symptoms is concerning because ECP therapy often
requires several weeks to see improvement. Likewise,
he would require careful management with his
degree of thrombocytopenia through the line place-
ment and the procedure. At least in 1 trial patients
with thrombocytopenia also had a lower rate of
response to ECP [5].
Fifty-four percent of respondents recommended
mycophenolate mofetil (MMF). MMF has been used
in steroid-refractory cGVHD and is the most com-
monly used second-line agent. There have been a num-
ber of small phase II trials reported using MMF, with
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from 45% to 75% [6]. Although the drug is well toler-
ated in general, in our experience it would be difficult
to administer in this patient given his mouth sores,
weight loss, and thrombocytopenia. Mycophenolic
acid (MPA) drug levels may prove useful in ensuring
he is receiving an adequate trial. Rituximab (10% of re-
sponders) is also appealing given its low toxicity, pos-
itive effects in immune thrombocytopenia, and
unique mechanism of action. However, rituximab
may be less effective for visceral disease, such as the
rapidly progressive hepatic involvement seen in this
patient [7]. Sirolimus (15% of responders) has been
studied also in phase II trials of cGVHD [8]. When
combined with tacrolimus and steroids, response rates
of more than 60% have been reported. The major tox-
icity seen with this combination was renal. Again, ob-
taining blood levels may help to minimize toxicities
and ensure an adequate trial of treatments.
We would encourage the patient to enroll in a clin-
ical trial, if one is available. If the patient is unable to
participate in a trial, then of the potential treatments
listed above, we would first try sirolimus because of
its mechanism of action and encouraging results re-
ported so far. However, both MMF and rituximab
are also reasonable choices. Because this patient is
showing some worrisome features of aGVHD, it
would be reasonable concurrently with starting the
new therapy also to administer a 3- to 7-day course
of prednisone at 2 mg/kg/day or a 4-day pulse of intra-
venous methylprednisolone at 10 mg/kg/day for more
rapid disease control and then go back immediately to
previous dose of prednisone [9].
As stated above, the best therapy is not known, and
it is unfortunately a matter of trial and error based on
toxicity profiles, past experience, and patient choice.cGVHD remains a great challenge, and major com-
munity efforts will need to continue to better address
this late effect of transplantation.
Steven Pavletic, MD,1 Georgia B. Vogelsand, MD,2
1National Cancer Institute, Bethesda, Maryland
2Johns Hopkins University, Baltimore, MarylandADDITIONAL READING
1. Martin PJ, Weisdorf D, Przepiorka D, et al. National Institutes of
Health consensus development project on criteria for clinical tri-
als in chronic graft-versus-host disease: VI. Design of Clinical
Trials Working Group report. Biol Blood Marrow Transplant.
2006;12:491-505.
2. Jagasia M, Giglia J, Chinratanalab W, et al. Incidence and out-
come of chronic graft-versus-host disease using National Insti-
tutes of Health Consensus Criteria. Biol Blood Marrow
Transplant. 2007;13:1207-1215.
3. Shlomchik WD, Lee SJ, Couriel D, Pavletic SZ. Transplanta-
tion’s greatest challenges: advances in chronic graft-versus-host
disease. Biol Blood Marrow Transplant. 2007;13:2-10.
4. Vogelsang GB, Wolff D, Altomonte V, et al. Treatment of
chronic graft-versus-host disease with ultraviolet irradiation and
psoralen (PUVA). Bone Marrow Transplant. 1996;17:1061-1067.
5. Couriel D, Hosing C, Saliba R, et al. Extracorporeal photophere-
sis for acute and chronic graft-versus-host disease: does it work?
Biol Blood Marrow Transplant. 2006;12:37-40.
6. Cutler C, Antin JH. Chronic graft-versus-host disease. Curr Opin
Oncol. 2006;18:126-131.
7. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refrac-
tory chronic graft-versus-host disease. Blood. 2006;108:756-762.
8. Couriel DR, Saliba R, Escalon MP, et al. Sirolimus in combination
with tacrolimus and corticosteroids for the treatment of resistant
chronic graft-versus-host disease.Br JHaematol. 2005;130:409-417.
9. Akpek G, Lee SM, Anders V, Vogelsang GB. A high-dose pulse
steroid regimen for controlling active chronic graft-versus-host
disease. Biol Blood Marrow Transplant. 2001;7:495-502.
